| 영문 | VDRL(venereal disease research laboratory) | 한글 | 성병 연구실험실 |
|---|---|---|---|
| 설명 | 매독균의 reagin에 대한 항체. 매독의 선별검사로 사용되며 매독 치료에 대한 반응 여부와 치료효과 판정에도 사용된다. 매독외에도 전신성홍반성낭창, 류마티스관절염 등에서도 양성으로 나타날 수 있다. |
||
| 영문 | Dilatation and Curettage(D & C) | 한글 | 자궁긁어냄술, 자궁목확장 |
|---|---|---|---|
| 설명 | 자궁이란 태아가 수태되어서 분만전까지 발육하고 성장하는 공간이다. 자궁속에 병변이 있어 임신이 계속될 수 없거나 아니면 다른 이유로 임신되어 있는 태아를 제거하고자 할 경우에 사용되는 방법이다. 여기서 긁어내기 위하여는 우선 자궁의 입구에 해당하는 자궁목을 확장시켜야 한다. 여기에는 급속히 확장을 시도하는 법과 서서히 확장을 시도하는 2가지 방법이 있다. 자궁목을 급속히 확장할 때는 헤가르 목관확장기(Hegar's dilatator)를 사용한다. 이것은 작은 금속막대로 작은 크기부터 큰 크기까지 다양한 크기가 있어서 우선 작은 막대로 시작하여 점점 큰 크기의 막대를 자궁목에 넣어서 자궁목을 확장시킨다. 서서히 확장시킬 때는 Laminaria tent를 목관에 삽입하는 방법을 사용한다. Laminaria tent란 해초로 만든 작은 막대로 수분을 흡수하면 점점 늘어나는 성질이 있다. 이것을 자궁의 목에 넣으면 이것이 수분을 흡수하여 늘어나므로 천천히 자궁의 목이 늘어난다. 자궁목이 충분히 늘어나면 그 속으로 끝이 숟가락처럼 생긴 기구를 넣어서 자궁속의 병변이나 임신된 태아를 긁어내는데 여기에 사용되는 숟가락처럼 생긴 기구를 큐렛이라고 한다. 초기 임신중절 즉 유산과 같은 임신과 관련된 경우뿐만 아니라, 비임신 자궁의 자궁내막조직의 채취 및 제거를 위해서도 행해지는 수기이다. 이는 원칙적으로 마취하에 실시되는 것으로 자궁목관을 확장하고 기구로 자궁 내용물을 제거하고 큐렛으로 자궁내벽을 깨끗이 한다. 자궁천공이나 자궁목의 파열 등의 위험이 따르며, 수술후 감염 또는 출혈 등에 대한 주의가 필요하다. |
||
| 영문 | prostaglandin(s)=PG(s) | 한글 | 푸로스타글란딘 |
|---|---|---|---|
| 설명 | 세포막의 인지질이 인지질 분해효소-A2에 의하여 유리된 arachidonic acid의 대사산물 중 cyclooxygenase에 의하여 형성된 물질. 여러 가지 종류가 있으며 복잡한 약리 작용을 한다. 대개, 혈관을 확장시키며, 민무늬근을 수축 또는 이완시키는데, 특히 자궁과 기관지근에 예민하게 작용한다. 종류를 보면, PGI2는 강력한 혈소판 응집 억제 작용을 하며, PGE계통은 위산분비 및 펩신분비를 강력히 억제시키며, 이자분비도 억제한다. 그 외 체온 조절 및 동통의 신경전도 등 아주 많은 작용을 하는 인체에 아주 중요한 물질이다. |
||
| TB | Taussig-Bind [syndrome]; terabyte; term birth; terminal bronchiole; terminal bronchus; thromboxane B... |
|---|---|
| TBX | thromboxane; total body irradiation |
| TBXA2 | thromboxane A2 |
| TBXAS | thromboxane A synthase |
| Thx | thromboxane |
| TXA2/PGH2 | Thromboxane A2/prostaglandin H2 |
|---|---|
| AHCPR | Agency for Health Care Policy and Research |
| AHRQ | Agency for Health Care Research and Quality |
| CBER | Center for Biologics Evaluation and Research |
| CDER | Center for Drug Evaluation and Research |
thromboxane
acute angle
| prostaglandin endoperoxide thromboxane isomerase | <enzyme> Converts prostaglandin h2 to thromboxane b2 and 12l-hydroxy-5,8,10-heptadecatrienoic acid Registry number: EC 5.3.99.- Synonym: endoperoxide-tx isomerase, pg endoperoxide thromboxane isomerase (26 Jun 1999) |
|---|---|
| united states agency for health care policy and research | An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research. (12 Dec 1998) |
| receptors, thromboxane | Cell surface proteins that bind thromboxanes with high affinity and trigger intracellular changes influencing the behaviour of cells. at least a subset of thromboxane receptors act via the inositol phosphate and diacylglycerol second messenger systems. (12 Dec 1998) |
| thromboxane | <biochemistry> Arachidonic acid metabolites produced by the action of thromboxane synthetase on prostaglandin cyclic endoperoxides. Thromboxane A2 (TxA2) is a potent inducer of platelet aggregation and release and although unstable, the activation of platelets leads to the further production of TxA2. Also causes arteriolar constriction. Another endoperoxide product, prostacyclin, has the opposite effects. (18 Nov 1997) |
| thromboxane a2 | <chemical> An unstable intermediate between the prostaglandin endoperoxides and thromboxane b2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (rcs). Chemical name: Thromboxa-5,13-dien-1-oic acid, 9,11-epoxy-15-hydroxy-, (5Z,9alpha,11alpha,13E,15S)- (12 Dec 1998) |
| thromboxane-a synthase | <enzyme> An enzyme found predominantly in platelet microsomes. It catalyses the conversion of pgg(2) and pgh(2) (prostaglandin endoperoxides) to thromboxane a2. Chemical name: (5Z,13E)-(15S)-9alpha,11alpha-Epidioxy-15-hydroxyprosta-5,13-dienoate thromboxane-A(2)-isomerase Registry number: EC 5.3.99.5 (12 Dec 1998) |
| thromboxane b2 | <chemical> A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). Chemical name: Thromboxa-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,13E,15S)- (12 Dec 1998) |
| thromboxane dehydrogenase | <enzyme> Converts thromboxane b2 to 11-dehydro-thromboxane b2, but not the reverse reaction; uses nad but not nadp as cofactor; only attacks the 11-hydroxy group of txb2 Registry number: EC 1.1.1.- Synonym: thromboxane b2 dehydrogenase, 11-hydroxythromboxane b2 dehydrogenase, 11-hydroxy-txb2 dehydrogenase (26 Jun 1999) |
| receptors, prostaglandin | Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behaviour of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin d2 (dp receptors), prostaglandin e2 (ep1, ep2, and ep3 receptors), prostaglandin f2-alpha (fp receptors), and prostacyclin (ip receptors). (12 Dec 1998) |
| receptors, prostaglandin e | Cell surface receptors which bind prostaglandins with a high affinity and trigger intracellular changes which influence the behaviour of cells. Prostaglandin e receptors prefer prostaglandin e2 to other endogenous prostaglandins. They are subdivided into ep1, ep2, and ep3 types based on their effects and their pharmacology. (12 Dec 1998) |
| prostaglandin | <protein> (prostate gland + in because they were originally discovered in semen) any of a group of components derived from unsaturated 20 carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway that are extremely potent mediators of a diverse group of physiologic processes. The abbreviation for prostaglandin is PG, specific compounds are designated by adding one of the letters A through I to indicate the type of substituents found on the hydrocarbon skeleton and a subscript (1, 2 or 3) to indicate the number of double bonds in the hydrocarbon skeleton for example, PGE2. The predominant naturally occurring prostaglandins all have two double bonds and are synthesised from arachidonic acid (5, 8, 11, 14 eicosatetraenoic acid) by the pathway shown in the illustration. The 1 series and 3 series are produced by the same pathway with fatty acids having one fewer double bond (8, 11, 14 eicosatrienoic acid or one more double bond (5, 8, 11, 14, 17 eicosapentaenoic acid) than arachidonic acid. The subscript a or á indicates the configuration at C 9 (a denotes a substituent below the plane of the ring, á, above the plane). The naturally occurring PGF's have the a configuration, for example, PGF2a. All of the prostaglandins act by binding to specific cell surface receptors causing an increase in the level of the intracellular second messenger cyclic AMP (and in some cases cyclic GMP also). The effect produced by the cyclic AMP increase depends on the specific cell type. In some cases there is also a positive feedback effect. Increased cyclic AMP increases prostaglandin synthesis leading to further increases in cyclic AMP. Group of compounds derived from arachidonic acid by the action of cyclooxygenase that produces cyclic endoperoxides (PGG2 and PGH2) that can give rise to prostacyclin or thromboxanes as well as prostaglandins. Were originally purified from prostate (hence the name), but are now known to be ubiquitous in tissues. PGs have a variety of important roles in regulating cellular activities, especially in the inflammatory response where they may act as vasodilators in the vascular system, cause vasoconstriction or vasodilation together with bronchodilation in the lung and act as hyperalgesics. Prostaglandins are rapidly degraded in the lungs and will not therefore persist in the circulation. Prostaglandin E2 PGE2) acts on adenylate cyclase to enhance the production of cyclic AMP. (18 Nov 1997) |
| prostaglandin antagonists | Compounds that inhibit the action of prostaglandins. (12 Dec 1998) |
| prostaglandin d2 | <chemical> 9,15-dihydroxy-11-oxoprosta-5,13-dien-1-oic acid. The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesised by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. Chemical name: Prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-oxo-, (5Z,9alpha,13E,15S)- (12 Dec 1998) |
| prostaglandin E1 | <chemical> A potent vasodilator agent that increases peripheral blood flow. It inhibits platelet aggregation and has many other biological effects such as bronchodilation, mediation of inflammation, etc. Pharmacological action: fibrinolytic agent, platelet aggregation inhibitors, vasodilator agents. Chemical name: Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)- (12 Dec 1998) |
| prostaglandin E1 monooxygenase | <enzyme> Requires NADPH; liver microsome enzyme is cytochrome p-450 dependent; catalyses omega hydroxylation Registry number: EC 1.14.- Synonym: pge1 monooxygenase (26 Jun 1999) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|